Plant-derived lignans as potential antiviral agents: a systematic review

Abstract

Medicinal plants are one of the most important sources of antiviral agents and lead compounds. Lignans are a large class of natural compounds comprising two phenyl propane units. Many of them have demonstrated biological activities, and some of them have even been developed as therapeutic drugs. In this review, 630 lignans, including those obtained from medicinal plants and their chemical derivatives, were systematically reviewed for their antiviral activity and mechanism of action. The compounds discussed herein were published in articles between 1998 and 2020. The articles were identified using both database searches (e.g., Web of Science, Pub Med and Scifinder) using key words such as: antiviral activity, antiviral effects, lignans, HBV, HCV, HIV, HPV, HSV, JEV, SARS-CoV, RSV and influenza A virus, and directed searches of scholarly publisher’s websites including ACS, Elsevier, Springer, Thieme, and Wiley. The compounds were classified on their structural characteristics as 1) arylnaphthalene lignans, 2) aryltetralin lignans, 3) dibenzylbutyrolactone lignans, 4) dibenzylbutane lignans, 5) tetrahydrofuranoid and tetrahydrofurofuranoid lignans, 6) benzofuran lignans, 7) neolignans, 8) dibenzocyclooctadiene lignans and homolignans, and 9) norlignans and other lignoids. Details on isolation and antiviral activities of the most active compounds within each class of lignan are discussed in detail, as are studies of synthetic lignans that provide structure–activity relationship information.

Introduction

A virus is a small infectious agent ranging from ~ 20 nm to 300 nm in diameter and contains mostly bundles of gene strands of either RNA or DNA as its genome. Viruses are not autonomous organisms and require the host cell environment and cellular factors for their propagation (Bekhit and Bekhit 2014). Due to the intracellular properties of viruses, it is often difficult to design a treatment that inhibits viral replication directly without adverse effects on the infected cells. (Zinser et al. 2018; Bar-On et al. 2018).

Viral infections can be categorized as chronic or acute based on the length of time the infections and symptoms last. Some of the viruses causing the most widespread and harmful chronic infections are hepatitis B virus (HBV), hepatitis C viruses (HCV), herpes simplex virus (HSV), human immunodeficiency virus (HIV), and human papilloma virus (HPV). HIV alone has caused approximately 33 million deaths since the virus was first discovered in 1981 (WHO 2021). Acute viral infections cause several of the most common, severe and rapid infections. This was painfully illustrated in the coronavirus disease 2019 (COVID-19) pandemic (Wu and McGoogan 2020). As of Mar 2021, there are over 123 million confirmed SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infected cases worldwide and over 2.7 million COVID-19 deaths (Worldometer 2021). Annually, seasonal influenza epidemics usually cause 250,000–500,000 deaths. However, they could also cause far more severe damage to human lives. For example, the 1918 H1N1 Spanish flu killed an estimated 50 million people, making it one of the worst pandemics in recorded human history (Short et al. 2018). The viral outbreaks like the Ebola virus (EBOV) in West Africa in 2014 received extensive media coverage due to its epidemic potential and high mortality rates of up to 90% (Martinez et al. 2014).

Many compounds have been tested on various viruses for their antivirtal activity in the past few decades, and some novel antiviral compounds are currently in the process of either preclinical or clinical trials (Chaudhuri et al. 2018). Although public health measures and prophylactic vaccines should remain the most effective means for prevetion of virus infection, for many virues vaccines are either not available or are inefficient. In addition, drug resistance is becoming increasingly common due to the expanding numbers of antiviral drugs. Long-term treatment with antiviral nucleoside analogues can cause delayed and, at times, severe mitochondrial toxicity. Kidney injury associated with antiviral drug use involves diverse mechanisms affecting renal transporters and tubule cells (Hussain et al. 2017; Izzedine et al. 2005). Therefore, the ongoing need to fight viral infections requires continued partnerships between medicinal chemists and biomedical researchers to identify and develop novel antiviral agents that are highly efficacious and cost-effective for the management and control of viral infections when vaccines and standard therapies are unavailable or ineffective.

Globally, medicinal plants have been used in traditional health care systems since ancient times and are still the most important source of medicines for the vast majority of the world’s population (Pushpa et al. 2013). Many traditionally used medicinal plants display strong antiviral activities, and some of them are used to treat animals and people who suffer from viral infections. In 2006, polyphenon E®, a partially-purified extract of green tea (Camellia sinensis) was approved as the first ever botanical drug by the US FDA to treat genital warts caused by HPV. Furthermore, recent studies showing the antiviral potential of plant extracts against viral strains resistant to conventional antiviral agents have contested modern drug discovery practices (Akram et al. 2018). Therefore, exploring the natural antiviral constituents of medicinal plants has garnered widespread and increased interest.

During the last 30 years, numerous broad-based screening programs have been carried out throughout the world to evaluate the inhibitory effects of medicinal plants on several viruses using in vitro and in vivo assays. For example, the Boots drug company (Nottingham, England) screened 288 plants for anti-influenza activity, and 12 of these plants were discovered to be effective against influenza viruses (Mukhtar et al. 2008). In another study, a joint international drug discovery program evaluated the antiviral effects of 3,760 plants extracts in Vietnam and Laos, which led to the identification of more than 90 plant leads that showed anti-HIV and anti-bird flu virus activities (Zhang et al. 2016; Rumschlag-Booms et al. 2011).

Lignans, constituted by the union of two phenylpropane units, are a large class of plant secondary metabolites with diversified chemical structures with many being biologically active including the US FDA approved anticancer drugs etoposide and teniposide (Newman and Cragg 2020). They have been found rich in fruits, seeds and vegetables, and received widespread interest due to their various biological activities including antioxidant, antitumor, antibacterial, antiviral, insecticidal, fungistatic, estrogenic, and antiestrogenic activities (Teponno et al. 2016). Their activity against the coronavirus SARS 2003 was also reported to be prominent (Wen et al. 2007).

The first antiviral lignan reported is podophyllin, a toxic lignan obtained from Podophyllum peltatum with antiviral activity against papilloma virus in 1942 (Kaplan 1942). Charlton had reviewed 49 natural lignans with antiviral activity from 1942 to 1997 (Charlton 1998). In a recent review article, Cui et al. reported about 25 representative lignans that showed antiviral activities (Cui et al. 2020). However, more than 600 lignans have been reported for their antiviral effects since 1998, and many of them showed potent properties. It’s therefore necessary to present a systematic review to include these antiviral lignans.

The present review summarizes the natural antiviral lignans or derivatives from 1998 to 2020. The lignans will be classified in 9 categories according to their chemical structure classes. Their antiviral activities against HIV, HBV, HCV, SARS, herpes simplex virus (HSV), HPV, Ebola virus, influenza virus, vesicular stomatitis virus (VSV) and other viruses will be discussed in detail. The antiviral mechanism studies of lignans will also be included when they were reported.

Arylnaphthalene-type lignans

In arylnaphthalene lignans, a naphthalene ring-system is made with carbons 1–8 and 7′ and 8′. There have been numerous arylnaphthalene lignans discovered from natural sources. Among the most common structural motifs found in this class of lignans, as with all classes of lignans, are various substitutions on the aromatic rings, a lactone moiety formed from C-8, C-9, C-8′, and C-9′, and glycosides. Many lignans in this class showed significant and broad antiviral activities, warranting them for further chemical and biological approaches for antiviral drug development.

Between 1998 and 2020, 17 arylnaphthalene lignans were isolated from plants and tested for antiviral activity (1–13, 32, 152 and 153) (see Table 1 for source plants, antiviral activities, and references). Of particular interest due to their potent antiviral activity (< 1 μM), are 2 and 11. We found four studies on synthetic arylnaphthalene lignans which displayed significant antiviral activities and provided information about structure–activity relationships.

Table 1.

Natural lignans from plants and their antiviral activities

Source	Parts	Compounds	Activity	Activity value	References
Daphne acutiloba Rehd. (Thymelaeaceae, Yunnan, China)	Leaves and stems	1	HIV-1	EC50 15.6 μM, TI 35.62	Cao et al. (2010)
Eucalyptus globoidea Blakely (Myrtaceae, Australia)	Buds	2	HIV integrase	EC50 0.64 μM	Ovenden et al. (2004)
Iryanthera megistophylla A. C. Sm. (Myristicaceae, Colombia)	Bark	3	HSV-1	EC50 > 1150 μM	Ming et al. (2002)
Phyllanthus acutissima Miq. (Euphorbiaceae, Thailand)	Aerial parts	4,5	HIV-1	4 EC50 < 7.4 μM	Tuchinda et al. (2008)
Phyllanthus flexuosus (Sieb. Et Zucc.) Muell. Arg (Euphorbiaceac, Yunnan, China)	Roots	6–10	HSV-1	inactive, EC50 value unavailable	Zhao et al. (2014)
Justicia procumbens var. leucantha (Acanthaceae, Tokyo, Japan)	Aerial parts	11	VSV V-ATPase	VSV MIC 0.66 μM; V-ATPase IC50 0.04–0.49 μM	Asano et al. (1996); Chen et al. (2013)
Phyllanthus myrtifolius Moon. (Euphorbiaceae, Taiwan, China)	Aerial parts	12–13	HIV-1	12 EC50 3.5 μM; 13 EC50 5.5 μM	Chang et al. (1995)
Taiwania cryptomerioides Hayata (Taxodiaceae, Taiwan, China)	aerial parts	32	HBV	EC50 1 μM	Yeo et al. (2005)
Justicia gendarussa Burm. f. and Justicia cf. patentiflora Hemsley (Acanthaceae, Vietnam)	Roots and stems	151–153	Drug-resistant HIV-1	152, 153 EC50 47–495 nM	Zhang et al. (2017a); Zhang et al. (2017b)
Symplocos setchuensis Brand. (Sympocaceae, Sichuan, China)	Stems	154	HIV replication	EC50 value unavailable	Ishida et al. (2001)
Parakmeria yunnanensis Hu. (Magnoliaceae, Yunnan, China)	Leaves and stems	154–156	HIV	155 EC50 250 μM 156 EC50 240 μM	Shang et al. (2013b)
Streblus asper Lour. (Moraceae, Guangxi, China)	Roots	157, 158	HBV	157 anti-HBsAg EC50 3.67 μM; anti-HBeAg EC50 14.67 μM; 158 anti-HBsAg EC50 6.98 μM, anti-HBeAg EC50 26.74 μM	Li et al. (2013)
Streblus asper Lour. (Moraceae, Guangxi, China)	Stem bark	158–160	HBV	158 HBsAg 6.58 μM, HBeAg 24.86 μM; 159 HBsAg 39.56 μM, HBeAg 61.23 μM	Li et al. (2012a)
Schisandra propinqua (Wall.) Hook. F. et Thoms. var. sinensis Oliv. (Schisandreae, Sichuan, China)	Aerial parts	162–165	anti-HIV-1	162 EC50 4.5 μM; 165 EC50 4.5 μM	Li et al. (2012b); Li et al. (2009a); Lei et al. (2007)
Schisandra sphenanthera Rehd. et Wils (Schisandraceae, Shanxi, China)	Fruits	166–169	HSV-2 adenovirus	166–169 HSV-2 EC50 31.6, 65.7, 65.7, 68.4 μM; adenovirus EC50 59.7, 126.8, 131.3, 100.5 μM	Song et al. (2013)
Carissa spinarum L. (Apocynaceae, Thailand)	Stems	170, 249–250, 337, 342, 343, 389	HSV-1, HSV-2	EC50 values > 100 μg	Wangteeraprasert et al. (2012)
Zanthoxylum ailanthoides Sieb. & Zucc. (Rutaceae, Taiwan, China)	Root bark	171–172	HIV	EC50 > 238 μM	Cheng et al. (2005b)
Strobilanthes cusia Bremek. (Acanthaceae, Japan)	Roots	173–174	HSV-1	173 EC50 > 172 μM; 174 EC50 > 141 μM	Tanaka et al. (2004)
Polygonum multiflorum Sieb. Et Zucc. (Polygonaceae, Shanghai, China)	Roots	175, 176	HIV-1	175 EC50 136.1 μM; 176 EC50 162.1 μM	Lin et al. (2010)
Phyllanthus species (Taiwan, China)	-	177–179	HBV	177 HBsAg and HBeAg EC50 value unavailable, 178 HBsAg EC50 value 36.9 μM, 179 HBsAg EC50 value > 50 μM, 178–179 BeAg EC50 value > 50 μM	Huang et al. (2003a)
Phyllantthus niruri L. (Euphorbiaceae, Guangxi, China)	Whole plants	178, 180–181	HBV	179–181 HBsAg EC50 97.2, 9.5, 16.7 μM; HBeAg EC50 232.1, 17.4, 69.3 μM	Wei et al. (2012)
Lindera glauca (Siebold & Zucc.) Blume (Lauraceae, Korea)	Twigs	171, 224–226	influenza A/PR8	171 and 225 with 30.1% and 29.3% virus infected Vero cells were survived with the treatment of 10 μM	Park et al. (2018)
Chamaecyparis obtusa (Cupressaceae, Taiwan, China)	Leaves	227	HSV-1	EC50 30.6 μM	Kuo et al. (2006)
Styrax japonica (Styracaceae, Korea)	Stem bark	228–230	HIV-1 virus cell fusion	228 fusion index 0.25, fusion inhibition 59.4% 229 fusion index 0.22, fusion inhibition 65.1%	Lee et al. (2010a)
Symplocos setchuensis (Symplocaceae, Sichuan, China)	Stems	230–232	HIV	231 EC50 2.0 μM; 232 EC50 6.9 μM	Ishida et al. (2001)
Bombax ceiba (Bombacaceae, Guangdong, China)	Roots	231, 233	HBV	231, HBsAg EC50 218.2 μM; 233, HBsAg EC50 123.7 μM	Wang et al. (2013)
Phenax angustifolius (Urticaceae, USA)	Leaves	234–238	HIV	234–238 EC50 3.0, 5.0, 0.8, 2.8, 5.2 μM	Piccinelli et al. (2005); Rastrelli et al. (2001)
Phyllanthus acutissima (Euphorbiaceae, Thailand)	Whole plants	239, 240	HIV	239 EC50 27.8 μM; 240 EC50 98.3 μM	Tuchinda et al. (2008)
Hernandia ovigera (Hernandiaceae, Taiwan, China)	Seeds	241, 242	EBV	470, 480 mol ratio/32 pmol TPA	Ito et al. (2001)
Phyllanthus species	–	243, 244	HBV	inhibition of HBsAg and HBeAg 33.9% and 68.3% at concentration of 50 μM	Huang et al. (2003a)
Chamaecyparis obtusa (Cupressaceae, Taiwan, China)	Heartwood	243, 245	SARS-CoV replication	243 EC50 > 10 μM, 245 EC50 1.13 μM	Wen et al. (2007)
Zanthoxylum ailanthoides (Rutaceae, Taiwan, China)	Root bark	243	HIV-1	243 EC50 < 0.28 μM	Cheng et al. (2005b)
Arctium lappa L.(Asteraceae, Osaka, Japan)	Fruits	246, 247	influenza A virus (A/NWS/33, H1N1)	246 EC50 24 μM, 247 EC50 3.8 μM	Hayashi et al. (2010)
Trachelospermum jasminoides (Lindl.) Lem	Stems, leaves	248	HCV	EC50 0.87 μM ( HCVcc model), 0.69 μM (HCVpp model)	Qian et al. (2016)
Brucea javanica (Simaroubaceae, Fujian, China)	Seeds	250	TMV	EC50 > 138 μM	Chen et al. (2009)
Machilus robusta (Lauraceae, Guangxi, China)	Bark	251–256	HIV-1 replication	inactive, EC50 value unavailable	Li et al. (2011)
Schisandra sphenanthera (Schisandraceae, Shaanxi, China)	Fruits	257–259	HSV-2, ADV	257–259 HSV-2, EC50 34.2, 160.1, 35.4 μM; ADV, EC50 68.4, 142.5, 224.7 μM	Song et al. (2013)
Schisandra sphenanthera (Schisandraceae, Shaanxi, China)	Leaves and stems	230, 260	HIV	233 EC50 31.5 μM	Liang et al. (2013)
Saururus chinensis rhizomes (Saururaceae, Korea)	Underground part	261	HIV-1	EC50 5.6 μM	Lee et al. (2010b)
Phyllanthus niruri (Euphorbiaceae, Guangxi, China)	Whole plants	262	HBV	HBsAg 15.6 μM, HBeAg 25.1 μM	Liu et al. (2014)
Schisandra rubriflora (Yunan, China)	Fruits	281	HIV-1	EC50 5.8 μM	Xiao et al. (2010a)
Kadsura angustifolia (Yunnan, China)	Stems	259, 282, 283	HIV-1	EC50 15.6, 27.0, 21.5 μM	Gao et al. (2008)
Schisandra propinqua (Sichuan, China)	Aerial parts	259, 279, 284, 285	HIV-1	EC50 4.0, 14.8, 9.4, 2.9 μM	Li et al. (2009b)
Schisandra chinensis (Heilongjiang, China)	Leaves and stems	286, 287	HIV-1	EC50 > 200 μM	Shi et al. (2014)
Daphne feddei (Thymelaeaceae, Yunnan, China)	Leaves and stems	288	HIV	EC50 23.2 μM	Hu et al. (2011)
Daphne acutiloba (Thymelaeceae, Yunan, China)	Stems	289, 290	HIV	290 EC50 0.64 μM	Huang et al. (2012)
Isatis indigotica (Brassicaceae, Anhui, China)	Roots	291	influenza, RSV, ADV, PIV3, EV71, HRV	influenza strains after viral adsorption, 137–1137 μM, RSV, ADV, PIV3, EV71, HRV inactive	Yang et al. (2013a)
Isatis indigotica (Brassicaceae, Anhui, China)	Roots	292	influenza A virus A/PR/8/34 (H1N1)	EC50 102 μM	Li et al. (2015)
Schisandra propinqua (Yunnan, China)	Fruits	293	HIV-1	EC50 15.9 μM	Fan et al. (2010)
Schisandra propinqua var. sinensis (Sichuan, China)	Aerial parts	294–297	HIV-1	294 + 295 EC50 7.7 μM	Li et al. (2009b)
Schisandra propinqua (Hubei, China)	Leaves and stems	298–306	HIV-1 IN DNA binding	EC50 > 25 μM	Shang et al. (2013a)
Schisandra rubriflora (Yunnan, China)	Fruits	307	HIV-1 IIIB induced syncytium formationHIV-1IIIB inducted MT-4 cells lytic effects	HIV-1 IIIB induced syncytium formation EC50 30.0 μM HIV-1IIIB inducted MT-4 cells lytic effects EC50 10.8 μM	Xiao et al. (2010a)
Schisandra chinensis (Heilongjiang, China)	Leaves and stems	308–309	HIV-1	309 EC50 66.1 μM	Shi et al. (2014)
Kadsura longipedunculata (Sichuan, China)	Leaves and stems	310–311	HIV-1	311 EC50 35.9 μM	Pu et al. (2008a)
Schisandra lancifolia (Yunnan, China)		312–313	HIV-1	312 EC50 212 μM, 313 EC50 149 μM	Xiao et al. (2010b)
Peperomia heyneana (Piperaceae, Yunnan, China)	Whole plants	314	HIV-1	EC50 50 μM	Zhang et al. (2007)
Saururus chinensis (Saururaceae, Guangxi, China)	Roots	315–323	EBV DNA replication	EC50 6.95–69.9 μM	Cui et al. (2014)
Brucea javanica (Simaroubaceae, Fujian, China)	Seeds	324–326	TMV replication	324–326 EC50 > 100 μM	Chen et al. (2009)
Parakmeria yunnanensis (Magnoliaceae, Yunnan, China)	Leaves and stems	327–333	HIV-1	EC50 > 80 μg/mL	Shang et al. (2013b)
Miliusa fragrans (Annonaceae, Thailand)	Leaves and stems	334–336	HSV-1, HSV-2	EC50 > 100 μg/mL	Sawasdee et al. (2013)
Fraxinus sinboldiana (Oleaceae, Korea)	Stems	337	HIV gp41 binding	EC50 > 266 μM	Kim et al. (2002)
Machilus robusta (Lauraceae, Guangxi, China)	Bark	326, 338, 339	HIV-1	inactive, EC50 value unavailable	Li et al. (2011)
Phyllanthus virgatus (Taiwan, China)	Whole plants	340	HBV	inactive, EC50 value unavailable	Huang et al. (2003a)
Phyllanthus flexuosus (Euphorbiaceae, Yunnan, China)	Roots	341	HSV-1	inactive, EC50 value unavailable	Zhao et al. (2014)
Herpetospermum caudigerum (Cucurbitaceae, Tibet, China)	Seeds	344, 345	HBV	HBsAg 344 EC50 317 μM, 345 EC50 629 μM, HBeAg 344 EC50 297 μM, 345 EC50 655 μM	Yuan et al. (2005)
Herpetospermum caudigerum (Sichuan, China)	Seeds	346–350	HBV	HBsAg 349 EC50 20.5 μM, 350 EC50 4.89 μM, HBeAg 349 EC50 3.54 μM, 350 EC50 8.02 μM	Yu et al. (2014)
Vitex leptobotrys (Lamiaceae, Vietnam)	Leaves and twigs	351, 352	HIV-1, EBV	351, 352 anti-HIV-1 inactive; 351 anti-EBV EC50 67 μM	Pan et al. (2014)
Litsea verticillata (Lauraceae, Vietnam)	Leaves and twigs	353, 354	HIV-1, EBV, HCMV	353 anti-HIV-1 EC50 42.7 μM; anti-EBV EC50 16.2 μM; 354 anti-EBV EC50 22.0 μM; anti-HCMV EC50 58.3 μM	Hoang et al. (2002); Guan et al. (2016)
Dipsacus asper (Dipsacaceae, Guizhou, China)	Roots	355–360	HIV-1	EC50 > 50 μM	Sun et al. (2015)
Ligularia kanaitizensis (Asteraceae, Yunnan, China)	Roots and rhizomes	361, 362	HIV RT	362 53.3% inhibition at 439 μM	Li et al. (2005c)
Hernandia ovigera (Hernandiaceae, Taiwan, China)	Seeds	363	EBV	590 mol ratio/32 pmol TPA	Ito et al. (2001)
Bombax ceiba (Bombacaceae, Guangdong, China)	Roots	343, 364	HBV	HBsAg 343 EC50 18.9 μM; 364 EC50 118.3 μM	Wang et al. (2013)
Citrus hystrix (Rutaceae, Thailand)	Roots	365	HIV-1	inactive, EC50 value unavailable	Panthong et al. (2013)
Forsythia suspensa (Oleaceae, Heilongjiang, China)	Fruits	343, 366–369	influenza A (H1N1)	inactive, EC50 value unavailable	Li et al. (2014)
Symplocos setchuensis (Symplocaceae, Sichuan, China)	Stems	343, 367	HIV-1	inactive, EC50 value unavailable	Ishida et al. (2001)
Calotropis gigantea (Asclepiadaceae, Thailand)	Latex	367, 370	influenza A (H1N1)	370 EC50 24.5 μM	Parhira et al. (2014)
Rhus javanica (Anacardiaceae, Taiwan, China)	Roots	343, 365, 367, 371–374	TMV	372–374 EC50 218, 280, 193 μM	Ouyang et al. (2007)
Swietenia macrophylla (Meliaceae, Taiwan, China)	Stems	375	HCV	EC50 10.5 μM	Wu et al. (2012)
Aster flaccidus bge (Asteraceae, Shanxi, China)	Roots	376	HIV-1	EC50 670 μM	Liu et al. (2010)
Forsythia suspensa (Oleaceae, Heilongjiang, China)	Fruits	377, 378	influenza A (H1N1), RSV	influenza A (H1N1), 378 EC50 41.1 μM, RSV 377 EC50 166.4 μM	Li et al. (2014)
Saururus chinensis (Saururaceae, Korea)	Rhizomes	379–382	HIV-1-induced cytopathic effects	379–381 EC100 1.0, 1.0, 0.2 μM	Lee et al. (2010b)
Saururus chinensis (Saururaceae, Guangxi, China)	Roots	321, 379–380, 383–388	EBV	321, 379–380, 383–388 EC50 6.95, 3.42, 1.72, 14.5, 7.55, 2.69, 3.52, 1.70, 1.09 μM	Cui et al. (2014)
Lindera glauca (Siebold & Zucc.) Blume (Lauraceae, Korea)	Twigs	365, 390–391	HRV1B and cvb3	391 against HRV1B and cvb3 with 75% and 90% virus infected Vero cells were survived with the treatment of 10 μM	Park et al. (2018)
Parakmeria yunnanensis (Magnoliaceae, Yunnan, China)	Leaves and stems	392	HIV-1	EC50 79.7 μM	Shang et al. (2013b)
Styrax japonica (Styracaceae, Korea)	Stem bark	393, 394	HIV-1 syncytia formation	393 and 394 percent fusion inhibition of 18.0% and 36.5% at the concentration of 20 μg/mL	Lee et al. (2010a)
Forsythia suspensa (Oleaceae, Heilongjiang, China)	Fruits	395–398	influenza A virus (H1N1)	396 EC50 60.5 μM	Li et al. (2014)
Streblus asper (Moraceae, Guangxi, China)	Roots	399, 400	HBV	EC50 > 1000 μM	Li et al. (2013)
Streblus asper (Moraceae, Guangxi, China)	Stem bark	399	HBV	EC50 > 1000 μM	Li et al. (2012a)
Piper regnelli (Piperaceae, Brazil)	Leaves	392	BHV-1, poliovirus	EC50 > 170 μM	Bertol et al. (2012)
Herpetospermum caudigerum (Cucurbitaceae, Tibet, China)	Seeds	401, 402	HBV	HBsAg, HBeAg EC50 > 100 μM	Yang et al. (2010a); Yuan et al. (2006)
Schisandra micrantha (Yunnan, China)	Leaves and stems	403	HIV-1	EC50 9.75 μM	Li et al. (2005a)
Kadsura angustifolia (Yunnan, China)	Stems	404, 405	HIV	EC50 40.86, 13.07 μM	Gao et al. (2008)
Schisandra lancifolia (Yunnan, China)	Leaves and stems	406	HIV-1	EC50 8.43 μM	Xiao et al. (2010b)
Schisandra sphenanthera (Shanxi, China)	Leaves and stems	407	HIV-1	inactive, EC50 value unavailable	Liang et al. (2013)
Illicium henryi (Illiciaceae, Yunnan, China)	Stems and roots	408–414	HBV	409 HBsAg EC50 60 μM	Liu et al. (2011)
Ailanthus altissima (Simaroubaceae, Fujian, China)	Root bark	415, 416	TMV	EC50 > 200 μg/mL	Tan et al. (2012)
Daphne feddei (Thymelaeaceae, Yunan, China)	Leaves and stems	417	HIV-1	EC50 27.7 μM	Hu et al. (2011)
Brucea javanica (Simaroubaceae, Fujian, China)	seeds	416	TMV	EC50 > 134 μM	Chen et al. (2009)
Streblus asper (Moraceae, Guangxi, China)	Stem bark	418–424	HBV	424 HBsAg EC50 2.03 μM; HBeAg EC50 3.76 μM	Li et al. (2012a)
Streblus asper (Sichuan, China)	Heartwood	423, 425–427	HBV	EC50 131.23–156.75 μM	Li et al. (2012c)
Streblus asper (Guangxi, China)	Roots	428, 429	HBV	429 HBsAg EC50 3.14 μM HBeAg EC50 4.74 μM	Chen et al. (2012)
Streblus asper (Guangxi, China)	Roots	423, 424, 430–437	HBV	423 and 437 EC50 2.03 and 1.58 μM for HBsAg, 3.76 and 3.24 μM for HBeAg, 8.67 and 9.02 μM for DNA replication	Li et al. (2013)
Kadsura interior (Yunnan, China)	Stems	442–455	EBV-EA	446, 447, 452, 453 showed inhibitory effects on relative ratio 7.1, 2.6, 4.7 and 9.4% at the concentration of 1000 mol ratio/TPA of EBV-EA activation	Chen et al. (2002)
Kadsura matsudai	Stems	456–474	HBV	456, 457 HBeAg EC50 90.1 and 94.3 μM	Kuo et al. (1999); Li et al. (2000); Kuo et al. (2001); Wu et al. (2003)
Schizandra arisanensis (Schizandraceous, Taiwan, China)	Stems	448, 475–477	HBV	EC50 > 50 μg/mL	Wu et al. (2003)
Kadsura japonica (Schizandraceous, Taiwan, China)	Stems	471, 472	HBV	HBsAg EC50 about 50 μM	Kuo et al. (2005)
Schisandra rubriflora (Schizandraceous, Yunnan, China)	Fruits	443, 444, 476–499	HIV-1	478, EC50 11.3; 480, EC50 < 0.65; 481, EC50 2.4; 477, EC50 5.7; 499, EC50 3.9 μM	Chen et al. (2006)
Schisandra rubriflora (Schizandraceous, Yunnan, China)	Aerial parts	443, 444, 477, 480, 488–492, 494, 495, 498	HIV-1	488, EC50 39.4; 489, EC50 36.9; 491, EC50 110 μM	Li et al. (2008)
Schisandra rubriflora (Schizandraceous, Yunnan, China)	Fruits	496, 497	HIV-1	496, EC50 4.77; 497 EC50 3.84 μM	Mu et al. (2011)
Kadsura longipedunculata (Schizandraceous, Yunnan, China)	Roots and stems	500–504	HIV-1	500 EC50 94.0 μM	Sun et al. (2006)
Kadsura induta (Schizandraceous, Yunnan Province, China)	Stems	452, 505–509	HBV	EC50 > 100 μg/mL	Ma et al. (2007)
Kadsura angustifolia (Schisandraceae, Yunnan, China)	Stems	373, 466, 492, 507–509, 577, 510–522	HIV-1	520 EC50 3.86 μM	Gao et al. (2008)
Kadsura heteroclita (Schisandraceae, Yunnan, China)	Stems	451, 453, 454, 521, 523–527	HIV-1	451, 527 EC50 3.3, 2.9 μM	Pu et al. (2008b)
Schisandra sphenanthera Rehd. Et Wils (Schisandraceae, Sichuan, China)	Leaves,stems	455, 498, 499, 528	HIV-1	455, 498, 499, 528 EC50 35.4, 39.4, 41.5, 35.9 μM	Xiao et al. (2008)
Schisandra propinqua vas. sinensis (Schisandraceae, Sichuan, China)	Aerial parts	449, 454, 519, 529–542	HIV-1	449 EC50 9.9 μM; 535 EC50 7.9 μM; 538 EC50 9.1 μM; 540 EC50 7.3 μM; 542 EC50 9.1 μM	Li et al. (2009b)
Schisandra lancifolia (Schisandraceae, Sichuan, China)	Leaves and stems	543–545	HIV-1	543–545 EC50 5.40, 9.30, 8.15 μM	Yang et al. (2010b)
Schisandra wilsoniana (Schisandraceae, Yunnan, China)	Fruits	455, 477, 482, 546–557	HBV	546 inhibitory effects on HBsAg and HBeAg secretion by 59.7% and 34.7% at a concentration of 97 µM	Ma et al. (2009)
Schisandra wilsoniana (Schisandraceae, Yunnan, China)	Fruits	553–555	HIV-1	553–555 EC50 8.1, 15.4, 6.9 μM	Yang et al. (2010d)
Schisandra wilsoniana (Schisandraceae, Yunnan, China)	Fruits	558–576	HIV-1	558–576 EC50 6.9, 13.6, 13.4, 6.2, 3.6, 3.3, 4.1, 6.5, 6.1, 4.1, 4.7, 3.5, 3.4, 6.2, 5.8, 3.2, 4.2, 3.9 and 4.1 μM	Yang et al. (2010c); Yang et al. (2013b)
Schisandra wilsoniana (Schisandraceae, Yunnan, China)	Fruits	443, 444, 447, 455, 476, 482–483, 485, 492, 498, 499, 556, 577–587	HIV-1, HBV	447, 498 anti-HIV-1 EC50 3.9, 5.5 μM; 556 anti-HBV on HBsAg and HBeAg secrtion by 59.7 and 34.7% at a concentration of 97 µM	Ma et al. (2013)
Schisandra neglecta (Schisandraceae, Yunnan, China)	Fruits	588, 589	HIV-1	588, 589 EC50 4.6, 5.8 μM	Duan et al. (2011)
Schisandra neglecta (Schisandraceae, Sichuan, China)	Fruits	583, 585, 590–598	HIV-1	583, 585, 590–598 EC50 4.7, 9.8, 2.2, 1.4, 5.9, 3.5, 8.2, 8.2, 8.3, 11.5, 8.3 μM	Gao et al. (2013)
Nicotiana tabacum (Solanaceae, Yunnan, China)	Leaves	599–604	HIV-1 TMV	599–604, anti-HIV-1 EC50 8.8, 4.6, 31.7, 20.4 μM; anti-TMV inhibition rate of 15.2, 58.4, 22.6 and 16.1% at the concentration of 20 μM	Gao et al. (2012)
Nicotiana tabacum (Solanaceae, Yunnan, China)	Roots,stems	600–604	TMV	600–604 anti-TMV inhibition rate of 14.7, 17.6, 21.4, 22.5 and 23.4% at the concentration of 20 μM	Liao et al. (2012)
Schisandra wilsoniana (Schisandraceae, Yunnan, China)	Stems	605–607	HIV-1	605–607 anti-HIV-1IIIB induced syncytia formation EC50 1.5, 4.5, 5.4 μM; 605 reduce p24 EC50 9.0 μM; inhibited primary isolate HIV-1TC-2 replication in PBMCs EC50 1.4 μM	Zhang et al. (2010)
Schisandra sphenanthera fruits (Schisandraceae, Shaanxi, China)	Fruits	608–610	HSV-2, adenovirus	608–610 anti-HSV-2 EC50 29.1, 122, 35.2 μM, anti-adenovirus EC50 96, 126, 105 μM	Song et al. (2013)
Schisandra lancifolia (Schisandraceae, Yunnan, China)	Leaves, stems	611	HIV-1	EC50 117 μM	Xiao et al. (2010b)
Herpetospermum caudigerum (Cucurbitaceae, Sichuan, China)	Seeds	612	HBV	HBsAg EC50 0.34 μM, HBeAg EC50 4.83 × 10–4 μM	Yu et al. (2014)
Parakmeria yunnanensis (Magnoliaceae, Yunnan, China)	Leaves and stems	613, 614	HIV-1	613 EC50 288 μM	Shang et al. (2013b)
Peperomia heyneana (Piperaceae, Yunnan, China)	Whole plants	615–617	HIV-1	615, 616 EC50 5.3, 5.4 μM	Zhang et al. (2007)
Schisandra sphenanthera (Schisandraceae, Shaanxi, China)	Fruits	618	HSV-2, adenovirus	HSV-2, EC50 42.7 μM; adenovirus EC50 55.0 μM	Song et al. (2013)
Schisandra lancifolia (Schisandraceae, Yunnan, China)	Fruits	619	HIV-1	EC50 1.82 μM	Li et al. (2009a)
Schisandra lancifolia (Schisandraceae, Yunnan, China)	Leaves and stems	620	HIV-1	EC50 30.3 μM	Xiao et al. (2010b)
Schisandra lancifolia (Schisandraceae, Yunnan, China)	Leaves and stems	621, 622	HIV-1	621, 622 EC50 8.6, 7.2 μM	Xue et al. (2011)
Schisandra wilsoniana (Schisandraceae, Yunnan, China)	Fruits	623–626	HIV-1	623–626 EC50 10.5, 9.8, 8.9, 7.6 μM	Yang et al. (2013b)
Kadsura angustifolia (Schisandraceae, Yunnan, China)	Stems	627, 628	HIV	627 EC50 44.68 μM	Gao et al. (2008)
Daphne feddei (Thymelaeaceae, Yunan, China)	Leaves and stems	627, 629–630	HIV	627, 629–630 EC50 104, 10.0, 8.3 μM	Hu et al. (2011)

Globoidnan A (2) was considered responsible for the inhibitory activity of HIV integrase of the extract of the buds of Eucalyptus globoidea Blakely (Australia). The lignan was found to inhibit the combined 3′-processing and strand transfer activity of HIV integrase with an EC₅₀ value of 0.64 μM (Ovenden et al. 2004). Diphyllin (11) from Justicia procumbens var. leucantha was determined to have antiviral activity with an MIC value of 0.66 µM against vesicular stomatitis virus (Asano et al. 1996). It was also identified as a novel v-ATPase blocker against influenza viruses (Chen et al. 2013). It could alter cellular susceptibility to influenza viruses through the inhibition of endosomal acidification, thus interfering with downstream viral replication, including that of known drug-resistant strains. Moreover, the combination treatment of the host-targeting diphyllin with pathogen-targeting therapeutics (oseltamivir and amantadine) has been reported to enhance the antiviral effects and cell protection in vitro (Chen et al. 2013; Shen et al. 2011).

Phyllamycin B (12) and retrojusticidin B (13), obtained from Phyllanthus myrtifolius Moon (Euphorbiaceae, Taiwan, China), exhibited inhibitory effects on HIV-1 RT with EC₅₀ values 3.5 and 5.5 µM. They showed less inhibition activities on human DNA polymerase-α (HDNAP-α) with EC₅₀ values more than 200 µM (Chang et al. 1995). Interest in the antiviral activities of 12 and 13 led to the synthesis and bioassay of 18 derivatives (14–31) including a range of nitrogen containing azalignans including 1-aryl-pyrronaphthalenes 23–27 and 3-N-alkylaminomethyl-1-arylnaphthalenes 28–31. The results indicated that compounds 17, 25, 26, and 31 have good activity against HIV, with EC₅₀ values of 0.77, 2.63, 0.02, 0.71 µM, respectively. It was noted that in the 9, 9′-γ-lactone series (16–18), the dicatechol 17 that contains four hydroxyl groups are much more active than the tetramethoxy (16) and dimethylenedioxy (18) derivatives. In addition, the N-isobutyl azalignans 26 and 31 were the most active among the series of compounds 23–31. Interestingly, N-isobutyl-pyrro[4,3-b]naphthalene (26) possessed the highest activity (EC₅₀ = 0.024 µM) with an excellent therapeutic index (TI) (6,000). Therefore, this compound could act as a lead compound for further anti-HIV drug development (Sagar et al. 2004).

Helioxanthin (32) was used as a scaffold to create 45 analogues (33–77) with particular attention paid to the lactone ring and methylenedioxy group, these synthetic analogs were evaluated for their antiviral activities against HBV, HCV, HSV-1, HSV-2, Epstein-Barr virus (EBV), cytomegalovirus (CMV) and HIV (Yeo et al. 2005). Of these analogues, the lactam 49 and the cyclic hydrazide derivative of helioxanthin (59) exhibited significant in vitro anti-HBV activity with EC₅₀ values of 0.08 and 0.03 µM, respectively, and compound 49 was also found to be the most potent HCV inhibitor (55% inhibition at the concentration of 1.0 µM). Compound 43, the acid-hydrolyzed product of the cyclic amide 40, displayed more potent activity than 32 against HBV with an EC₅₀ value of 0.8 µM. In addition, compounds 46 and 53, containing dimethoxy moieties instead of methylenedioxy groups in the C ring of compounds 43 and 49, displayed potent antiviral activities against HCV (64% and 80% inhibition at 3.0 µM, respectively) as well as HBV (EC₅₀ = 0.8 and 0.9 µM, respectively). Compounds 43 and 49 were found to be the strongest HSV inhibitors. They showed inhibitory activity against HSV-1 with EC₅₀ values of 0.15 and 0.29 µM, respectively, and against HSV-2 with EC₅₀ values of < 0.1 and 0.16 µM, respectively. Compound 43 was further determined to have broad-spectrum antiviral activity against HSV-1 (EC₅₀ = 0.15 µM), HSV-2 (EC₅₀ < 0.1 µM), EBV (EC₅₀ = 9.0 µM) and CMV (EC₅₀ = 0.45 µM). This compound was approximately 140 and 210 times more potent than the reference drug acylovir (EC₅₀ = 21 µM) against HSV-1 and HSV-2, respectively. The cyclic hydrazide 59 and its brominated product 73 showed anti-HIV activities with EC₅₀ values of 2.7 and 2.5 µM, respectively (Yeo et al. 2005). Moreover, as established by quantification of viral DNA, RNA, covalently closed circular DNA, and protein synthesis, compound 59 inhibited duck HBV (DHBV) activity without affecting the stability of cellular macromolecules, and it had a sustained antiviral effect even after drug removal. When DHBV replication was induced, virus-harbouring cells were more susceptible to the cytotoxicity of the compound than the non-induced cells (Ying et al. 2010).

In a study of inhibitors of HBV gene expression and replication, compound 32 and its lactam analogue 49 demonstrated strong anti-HBV activity by markedly decreasing HBV DNA, 3.5-kb and 2.4/2.1-kb RNA, and the core protein in HepG2.2.15 cells. Compounds 32 and 49 revealed EC₅₀ values of 1.0 and 0.08 µM against HBV DNA, and 1.0 and 0.09 µM against HBV RNA (3.5 kb), respectively. In addition, western blot analysis of the cell lysate from HepG2.2.15 cells confirmed that the core protein expression decreased in a dose-dependent manner after drug treatment. Moreover, the EC₅₀ values for compounds 32 and 49 as inhibitors of HBV DNA production were determined to be 0.4 µM and 0.004 µM against the drug-resistant mutant W10, and 0.1 µM and 0.0003 µM against the drug-resistant mutant DM2, respectively (Li et al. 2005b; Cheng et al. 2005a; Tseng et al. 2008).

In a study of the anti-HBV mechanism, compound 59 was found to suppress HBV RNA and protein expression as well as DNA replication of both the wild-type and 3TC-resistant virus. In addition, the time-course analyses revealed that RNA expression was inhibited first after treatment with compound 59, followed by viral proteins, and then DNA. This compound inhibited the activity of all HBV promoters by decreasing the binding of hepatocyte nuclear factor (HNF)-4, HNF-3, and fetoprotein factor to the precore/core promoter enhancer II region. Therefore, compound 59 suppressed HBV replication by posttranscriptional downregulation of critical transcription factors in HBV-producing cells, thus reducing HBV promoter activity and blocking viral gene expression and replication (Ying et al. 2007; Quasdorff & Protzer 2010).

Yeh et al. also synthesized series of helioxanthin analogues (78–110) by modification at the lactone rings. These compounds were evaluated for their anti-HBV activity in HepA2. Among them, helioxanthin (32) and the derivative 103 were found to possess the best activity (EC₅₀ = 0.16 µM and 0.14 µM, respectively), whereas the retro-isomer 79 (EC₅₀ = 2.18 µM) is less active. Interestingly, compound 105 differs from 103 only by switching the locations of the hydroxyl (OH) and the methoxy (OCH₃) groups, yet its anti-HBV activity was markedly reduced to an EC₅₀ value of 1.89 µM. The γ-lactam ring opening analogues 84, 89, 90 and 91 exhibited antiviral activity against HBV with EC₅₀ values of 0.89, 1.41, 0.42 and 1.22 µM, respectively. Analogues 93, 108 and 109 exhibited moderate to low anti-HBV effects (EC₅₀ = 2.39, 3.06 and 7.64 µM, respectively), while all other compounds did not display detectable anti-HBV effects within the same range of concentrations. Compound 103 potently suppressed both endogenously expressed HBsAg and HBeAg production with EC₅₀ values of 0.06 and 0.14 μM, respectively. It not only inhibited HBV DNA with wild-type (stably transfected with 1.3-fold wild-type HBV ayw strain genome in HepG2 cells) and lamivudine-resistant (HepG2 cell line [HBV] containing the lamivudine-resistant HBV with L515M/M539V double mutation in the DNA polymerase region) strains, but also suppressed all HBV transcripts and HBV core protein in 1.3 ES2 cells. Additionally, it could selectively suppress viral promoter activity for HBV surface antigen, core antigen and enhancer I in HepA2 cells (Janmanchi et al. 2010).

Helioxanthin analogues 103, 105, 108, 111–150) were also synthesized and evaluated for their anti-hepatitis B virus activity. Among them, 112 exhibited the strongest inhibition (EC₅₀ value 0.06 μM), which was about three times more active than its parent compound (32). Potent activities were also found for the fluorine containing 117, the γ-lactone ring opening 129–131 and the lactone group containing 147 with EC₅₀ values of 0.38, 0.67, 0.49, 0.65 and 0.86 μM, respectively. From these synthesized arylnaphthalene lignans, no distinguished structure–activity relationship could be concluded. However, it is obvious that the retro-lactonization and the ring opening of the lactone group do not lower the anti-HBV activity. The most effective compound, 112, not only suppressed HBsAg production in HepA2 cells and viral replication of HBV (stably transfected with 1.3-fold wild-type HBV ayw strain genome in HepG2 cells), but also inhibited all HBV transcripts in 1.3ES2 cells and viral core promoter activity in HepA2 cells (Janmanchi et al. 2013).

Justiprocumins A (151) and B (152), patentiflorin A (153) were obtained from Justicia gendarussa Burm. f. and Justicia cf. patentiflora Hemsley (Vietnam). Compounds 152 and 153 displayed potent activity against a broad spectrum of HIV strains with EC₅₀ values in the ranges of 15–37 nM (AZT, EC₅₀ 77–95 nM). They also showed potent inhibitory effects against drug-resistant HIV-1 isolates (HIV-1_1617–1/HIV-1_N119) of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine) with EC₅₀ values in the ranges of 47–495 nM (Zhang et al. 2017a, 2017b). In this study, the C-7 sugar unit-containing compounds (151, 153) display better anti-HIV activity than their aglycone diphylin (11). Compound 153 also exhibited potent inhibitory activity against Zika virus (ZIKV) infection in vitro and in vivo, a mosquito-borne flavivirus that causes microcephaly and severe brain malformations in fetus. It blocked ZIKV infection in African greenmonkey kidney epithelial cells (VERO), human fibroblast cells (HT1080), and human microglial cells (CHME3) with EC₅₀ values between 0.01–0.03 μM. The result was confirmed in vivo by using type I interferon receptor knockout mouse model C57BL/6 Ifnar1^−/−. Compound 153 also showed a broad spectrum inhibition against other Flaviviridae viruses including DENV1, tick-borne encephalitis virus (TBEV), West Nile virus (WNV), JEV and EBV with the EC₅₀ values ranged between 0.12–1.0 μM (Martinez-Lopez et al. 2019).

Aryltetralin-type lignans

Aryltetralin lignans have a 10-membered bicyclic core, with two aromatic ring systems. Unlike arylnaphthalene lignans, which involve all three rings being aromatized, aryltetralin lignans have a variety of configurations possible in the non-aromatic ring (ring B) formed by fusion of the two phenylpropanoid units. This leads to a greater diversity of possible isomers and stereochemical outcomes in aryltetralin lignans. We have included lignans bearing a dialin ring-system in this section, since they also contain stereocenters in the core of the molecule and are not typically recognized as a separate class of lignans. The most well-known lignan of this type of compounds may be podophyllotoxin. The compound was discovered from Podophyllum peltatum L. in 1880 (Cragg et al. 2011). Two of its derivatives, etopside and teniposide, were granted as anticancer medications by the US FDA in 1983 and 1992, respectively (Hande 1998; Cragg and Newman 2005).

During the time covered by this review, 31 aryltetralin lignans isolated from plants were tested for antiviral activity (154–181, 224–226) (see Table 1 for source plants, antiviral activities, and references). Of the plant-derived aryltetralin lignans, only compounds 157, 162, and 165 displayed antiviral activity at concentrations below 5 μM. There were three studies on synthetic podophyllotoxin analogues which displayed significant antiviral activities and provided information about structure–activity relationships.

In an ongoing study of the chemical composition of Streblus asper Lour. (Moraceae, Guangxi, China), Li et al. isolated (-)-isolariciresinol (157) and 9-β-xylopyranosyl-(-)-isolariciresinol (158) from the plant’s roots. In tests for potential inhibition of the secretion of HBV s antigen (HBsAg) and HBV e antigen (HBeAg), and the replication of HBV DNA in HBV-infected HepG2.2.15 cells, compounds 157 and 158 displayed anti-HBV activity of EC₅₀ values of 3.67 and 6.98 μM for HBsAg with TI values 35.28 and 30.15, and EC₅₀ values of 14.67 and 26.74 μM for HBeAg with TI values 8.82 and 7.87, respectively. In addition, the compounds showed inhibitory activity on the replication of HBV DNA with EC₅₀ values of 12.72 and 17.68 μM and TI of 10.18 and 11.90, respectively (Li et al. 2013). Compounds 158, 5-methoxy-9-β-xylopyranosyl-(-)-isolariciresinol (159) and 9-β-xylopyranosyl-lyoniresinol (160) were obtained from the stem bark. The only difference of 160 from 158 is that it contains an extra methoxyl group in ring C, and its difference from 159 is that it is lacking an methoxyl group in ring A. Compounds 158 and 159 inhibited the expression of HBsAg and HBeAg with EC₅₀ values of 6.58 and 39.56 μM for HBsAg (TI > 2), and 24.86 μM (TI = 8.06) and 61.23 μM (TI = 1.75) for HBeAg, respectively, while 160 showed no activity against HBV at the concentration of 1000 μM (Li et al. 2012a).

Three new aryltetralin lignans, sinensisins A-C (162–164) and the known (8R,7′R,8R)-5-hydroxy-4,3′,4′-trimethoxy-2,7′-cyclolignan (165) were isolated from the aerial parts of Schisandra propinqua (Wall.) Hook. F. et Thoms. var. sinensis Oliv. (Sichuan, China) and tested for HIV-1 inhibitory effects in a microtiter syncytium formation infectivity assay. Among them, both 162 and 165 displayed anti-HIV-1 activity with EC₅₀ values of 4.5 μM and TI values of 6.7 (Li et al. 2012b, 2009a; Lei et al. 2007).

Thirteen podophyllotoxin derivatives (182–194) containing modifications in the phenyl C-ring or the lactone ring were prepared and evaluated for their antiherpetic activity against HSV-2 on Vero cells. Among them, phenazines 192 and 193 showed the highest antiviral potency against HSV-2 (Castro et al. 2003).

A series of derivatives (195–216) of podophyllotoxin with structural modifications mostly at C-7 were synthesized and tested for their inhibitory effects of HIV-1 replication in acutely infected H9 cells. Among the derivatives, the 4-amino derivatives 213–216 were the strongest HIV inhibitors exhibiting EC₅₀ values of < 0.002 μM and TI values > 120. The 4-amino substituted compounds 199 and 203 also displayed strong HIV activity with EC₅₀ values of 0.021 and < 0.002 μM and TI values of 19.1 and > 16, respectively. The 4β-hydroxyl containing compound 197 and its corresponding vinyl carbamate 208 were the strongest HIV inhibitors among the non-nitrogen containing derivatives with EC₅₀ values of 0.14 and 0.072 μM, respectively. However, compound 210, which contains a 4α-hydroxyl group showed less inhibitory activity with an EC₅₀ value of 0.90 μM and a TI value of 19.4. Comparison of the anti-HIV activity of these derivatives suggested that the methylenedioxy group of C-4 and C-5 being substituted by two methoxy groups enhanced the anti-HIV activity (Zhu et al. 2004).

In 2007, a new series of podophyllotoxin derivatives (217–223) some of which contained the antiviral drug molecule stavudine and different structural podophyllotoxin analogues were designed, synthesized, and tested for their inhibitory activity against HIV-1 replication in acutely infected C8166 cells by Tu et al. Among these compounds, 219 and 220 showed the highest anti-HIV-1 activities with EC₅₀ values of 0.29 and 0.17 μM and TI values of 354.5 and 466.9, respectively. Moreover, the 7β–cyano-substituted 4,5–dimethoxy compound 222 also showed promising anti-HIV activity (EC₅₀ = 1.05 μM and TI = 131.28). However, compound 223, which is a carboxylic acid derivative of podophyllotoxin obtained by hydrolyzation of 222, was significantly less active than 222 with an EC₅₀ value of 46.90 μM and a TI value > 9.31 (Chen et al. 2007).

Dibenzylbutyrolactone-type lignans

Dibenzylbutyrolactone lignans are defined by the presence of a five-membered lactone ring formed by the cyclization of oxidized C-9 and C-9′ carbons. Similar to the aryltetralin lignans, this type of lignan may possess a wide variety of relative and absolute configurations, leading to a large number of isomers. The lactone ring in dibenzylbutyrolactone lignans is reminiscent of the lactones frequently observed in the structures of the previously discussed arylnaphthalene and aryltetralin lignans. Most of this type of lignan showed insignificant antiviral activity, although a few of them were studied in mice for their antiinfluenza activity.

From 1998 to 2019, 22 dibenzylbutyrolactone lignans were isolated from plants and tested for antiviral activity (227–248) (see Table 1 for source plants, antiviral activities, and references). Compounds 236, 243, 245, and 248 are worthy of additional discussion due to their potent antiviral activity (≤ 1 μM). Interestingly, considering the potent activity of the four aforementioned potently active compounds, we could find no studies on antiviral activities of synthetic dibenzylbutyrolactone lignans.

Phenaxolactones 1–5 (234–238) were isolated from the leaves of Phenax spp. (Urticaceae, USA). Compound 234 showed anti-HIV activity with an EC₅₀ value of 3.0 µM and TI value of 37.3. Compound 236 exhibited increased anti-HIV activity with an EC₅₀ value of 0.8 µM but lower TI value of 12.5, while 237, the glycosylated derivative of 236, showed less activity with an EC₅₀ of 2.8 µM and TI of 6.4. Moderate antiviral activity was observed for 235 (EC₅₀ of 5.0 µM and TI of 15.0) and 238 (EC₅₀ of 5.2 µM and TI of 14.4) (Piccinelli et al. 2005; Rastrelli et al. 2001).

Hinokinin (243), isolated from a Phyllanthus species, significantly inhibited both HBsAg and HBeAg production with inhibitions of 33.9% and 68.3% at a concentration of 50 µM, respectively. ( +)–trans–8-(3,4-(Methylenedioxybenzyl)-8′-(3′,4′-dimethoxybenzyl)-butyrolactone (244), and a tannin virgatyne were found to have no antiviral activity (Huang et al. 2003a). Purified from the heartwood of Chamaecyparis obtusa (Cupressaceae, Taiwan, China), 243 and savinin [245, the enantiomer of isogadian (240)] showed high inhibitory activity in the cell-based assay utilizing CPE on Vero E6 cells via SARS-CoV infection at the concentration of 20 μM. In the evaluation for inhibition of SARS-CoV replication using ELISA, 243 had an EC₅₀ value higher than 10 μM, but the EC₅₀ value of 245 was determined to be much more potent with a value of 1.13 μM (TI > 667). In the test for inhibitory effect of SARS-CoV 3CL protease activity, 243 and 245 displayed EC₅₀ values of > 100 and 25 µM, respectively, and a Ki value for 245 was determined to be 9.1 μM in the study of the inhibitory mechanism (Wen et al. 2007). Isolated from the root bark of Zanthoxylum ailanthoides (Rutaceae, Taiwan, China) as well, hinokinin (243) displayed significant anti-HIV-1 activity with an EC₅₀ value of < 0.28 μM and a TI value of > 18.7 in the test for inhibition of HIV replication (Cheng et al. 2005b).

Trachelogenin (248), obtained from the stems and leaves of Trachelospermum jasminoides (Lindl.) Lem., exhibited anti-HCV potential with EC₅₀ values of 0.87 μM (in HCVcc model) and 0.69 μM (in HCVpp model). Compound 248 was a HCV entry inhibitor by interfering with the interactions between HCV glycoprotein E2 and the host entry factor CD81 (Qian et al. 2016).

Dibenzylbutane-type lignans

Dibenzylbutane lignans bear the least modified connections between the 8 and 8′ carbons of the phenylpropanoid precursors. This class also contains a large number of stereoisomers due to the chiral carbons created by linking C-8 to C-8′. The carbons derived from C-9 and C-9′ are found in a variety of oxidation states varying from methyl groups to carboxylic acid functionalities. As with benzylbutyrolactones, this type of lignans is also lacking lead molecules that show attractive antiviral activities.

We found records of 29 dibenzylbutyrolactone lignans isolated from plants and tested for antiviral activity (249–262, 269, 280–287) (see Table 1 for source plants, antiviral activities, and references). Compounds 259 and 285 displayed the most activity in antiviral assays (< 5 μM). There were 10 synthetic dibenzylbutryolactones published between 1998 and 2020, most of which were modeled off of nordihydroguaiaretic acid (NDGA) (269).

Nordihydroguaiaretic acid (NDGA) (269), a lignan obtained from the leaves and twigs of Larrea tridentate, was evaluated for its anti-dengue virus (DENV) effects. It displayed a dose-dependent inhibitory effects on the viral yield and nonstructural protein-1 secretion in the supernatants of infected cells treated for 24 and 48 h. In DENV4 replicon-transfected Vero cells, treatment with 269 at 50 and 100 μM significantly reduced DENV replication. Furthermore, treatment with this compound not only led to the reduction in the number of lipid droplets (LDs), the neutral lipid storage organelles involved in DENV morphogenesis that are known to proliferate during DENV infection, but also resulted in dissociation of the C protein from LDs (Soto-Acosta et al. 2014). Compound 269 was assessed for its ability to elicit HIV replication. It was demonstrated to increase the HIV-1 p24 antigen two fold at the concentration of 15 μM. In addition, the treatment of 269 at 15 μM also increased reactive oxygen species production in U1 cells up to 140% compared with control cells (Barquero et al. 2014). Compound 269 was tested as an HPV16 E6 gene inhibitor. This compound was shown to inhibit HPV16 E6 mRNA expression, influence E6 gene transcription, and induce decreased protein expression levels of E6 and p53 (Chen et al. 2008). In an investigation on host lipid/fatty acid synthesis and the HCV life cycle, 269 canceled the HCV-induced alteration of host lipid homeostasis. This compound not only reduced sterol regulatory element-binding protein activation and increased the expression of the genes involved in β-oxidation, but it also inhibited very-low-density lipoprotein (VLDL) secretion by affecting mediators of VLDL biosynthesis. Whereas HCV induced the accumulation and perinuclear distribution of LDs, 269 decreased the overall number and increased the average size of the LDs (Syed and Siddiqui 2011). Furthermore, when 269 was added simultaneously with the virus, it could inhibit Junin viral replication (Konigheim et al. 2005).

Tetra-O-glycyl-NDGA (270), a water-soluble derivative of 269, competed effectively with the DNA binding domain of recombinant Sp1 protein to bind to the HIV long terminal repeat, as determined by an electrophoretic mobility-shift assay. By inhibiting Sp1 binding to the HIV long terminal repeat, 270 repressed Sp1-regulated HIV Tat transactivation and replication in cultured cells, with an EC₅₀ of 12 μM. Moreover, replication of simian immunodeficiency virus was completely blocked by 270 at a concentration of 5.0 μM. Furthermore, at 100 μM, 270 was harmless towards 174 × CEM cells and H9 cells (Huang et al. 2003b).

Nine synthesised NDGA derivatives 271–277, Mal.4 (278), and M₄N (279) inhibited Tat transactivation in a dose-dependent manner. At 80 μM, these compounds blocked Tat-regulated secreted alkaline phosphatase production by > 90%; and at 20 μM, the inhibition was still > 50%. All of these newly synthesized derivatives showed a greater inhibitory activity than the parent NDGA 269 (EC₅₀ = 20 μM) and Mal.4 (278, EC₅₀ = 25 μM). Except for compounds 271 (EC₅₀ = 17.2 μM) and 273 (EC₅₀ = 17.3 μM), all other NDGA derivatives demonstrated greater potency than M₄N (279, EC₅₀ = 11.1 μM). Compound 272 (EC₅₀ = 0.88 μM) was determined to be the strongest inhibitor of HIV Tat-regulated transactivation among all of the new NDGA derivatives (Hwu et al. 2008). Furthermore, three synthesized NDGA derivatives, tetra-acetyl NDGA (280), 278 and 279, were all demonstrated to inhibit gene expression from the early promoter P₉₇ of HPV16. Using luciferase activity as the indicator of gene expression, compounds 278 and 279 were shown to be active in a dose-dependent manner. However, 280 (EC₅₀ = 11 μM) was shown to be a better inhibitor of the HPV P₉₇ promoter activity than 278 (EC₅₀ = 37 μM) and 279 (EC₅₀ = 28 μM). These compounds demonstrated very little effect on the gene expression guided by the ADV major late promoter and the CMV promoter (Craigo et al. 2000; Halim et al. 2013). Compound 279 inhibited 10 passages of HSV-1 and 4 passages of HSV-2 with the EC₅₀ values ranges 4–11.7 μM, while the EC₅₀ ranges of ACV increased from 7 μM to 444 μM. The results indicated that 279 had less drug resistance than ACV. Compound 279 inhibited HSV by decreasing the expression of the HSV immediate early gene α-ICP4 with an EC₅₀ value of 43.5 μM, which was essential for HSV replication (Chen et al. 1998).

Compound 281, 3,3′-Dihydroxy-4,4′,5,5′-tetramethoxylignan, was isolated from the fruits of Schisandra rubriflora (Yunan, China). It showed inhibitory activity on HIV-1_IIIB induced syncytium formation with an EC₅₀ value of 5.8 µM and a TI value of 4.46 (Xiao et al. 2010a). Kadangustins H (282) and I (283), meso-dihydroguaiaretic acid (259), tiegusanin N (284), meso-monomethyldihydroguaiareticacid (285) and 279 were isolated from the stems of Kadsura angustifolia (Yunnan, China). The compounds showed anti-HIV activity with EC₅₀ values of 27.0, 21.5, 15.6/4.0, 2.9 and 14.8 μM, and TI values of 2.8, 1.1, 3.2/6.2, 5.8 and 2.0, respectively (Gao et al. 2008; Li et al. 2009b).

Tetrahydrofuranoid and tetrahydrofurofuranoid-lignans

Tetrahydrofuranoid lignans have a characteristic five-membered oxygen-containing ring connecting the two phenylpropanoid precursor units. This ring can be derived from a C-7 and C-8 to C-7′ and C-8′ linkage (7,8,8′,7′-tetrahydrofuranoid lignans, compounds 294–311, 313–323, 334–336, 338, 340, 379–388), a C-7 and C-8 to C-8′ and C-9′ linkage (7,8,8′,9′-tetrahydrofuranoid lignans, compounds 291, 292, 324, 325, 327, 337, 339, 344, 346, 347, 376–378, 390 and 391), or a C-8 and C-9 to C-8′ and C-9′ linkage (9,8,8′,9′-tetrahydrofuranoid lignans, compounds 288–290, 333 and 389). This diversity of precursor orientations, combined with the possibility of stereoisomers leads to a large diversity of possible isomers being isolated. Tetrahydrofurofuranoid lignans are defined by the presence of a bicyclic furofuran ring-system formed by the connection of C-7 to C-9′ through an oxygen atom, and a connection between C-9 and C-7′ through an oxygen atom (tetrahydrofurofuranoid lignans, compounds 293, 312, 326, 328–332, 341–343, 345, 348–375).

The antiviral activity of 104 plant-derived tetrahydrofuranoid and tetrahydrofurofuranoid lignans were reported between 1998 and 2020 (288–391) (see Table 1 for source plants, antiviral activities, and references). Five compounds in this class (290, 379–381, 388) displayed antiviral activity at concentrations of 1 μM or less. We did not find any antiviral studies on synthetic tetrahydrofuranoid or tetrahydrofurofuranoid lignans during the time period covered in this review.

4,4′-Dihydroxy-3,3′-dimethoxy-9-ethoxy-9,9′-epoxylignan (289) and daphnenin (290), are two lignans that were isolated from the stems of Daphne acutiloba (Thymelaeceae, Yunan, China). Compound 290 showed anti-HIV activity with an EC₅₀ value of 0.64 µM (Huang et al. 2012).

Manassantins A–B (379–380) and saucerneols B–C (381–382) were isolated from Saururus chinensis (Saururaceae, Korea) rhizomes and evaluated for their anti-HIV-1 activities. Compound 379 showed dose-dependent inhibitory activities on HIV-1 protease with an EC₅₀ value of 38.9 μM. Compounds 379–381 inhibited HIV-1-induced cytopathic effects in a human T lymphoblastoid cell line with EC₁₀₀ values of 1.0, 1.0 and 0.2 μM, respectively. Compound 381 showed the most potent and selective anti-HIV-1 activity with an EC₁₀₀ value of 0.2 μM, a CC₀ value of > 125.0 μM, and a TI value of > 520.8 (Lee et al. 2010b). Nine tetrahydrofuran lignans, (–)–(7"R,8"R)–saucerneol J (321), manassantins A–B (379–380), saurucinol B (383), 4′′-O-demethylmanassantin A (384), 3′′-O-demethylmanassantin B (385), 4–O–demethylmanassantin B (386), saucerneol methyl ether (387) and saucerneol D (388) were isolated from the roots of S. chinensis (Saururaceae, Guangxi, China). In the examination for their abilities to inhibit EBV lytic DNA replication in P3HR-1 cells, these compounds showed strong to moderate activities with EC₅₀ values of 6.95, 3.42, 1.72, 14.5, 7.55, 2.69, 3.52, 1.70 and 1.09 μM, and TI values of 3.3, 58.5, 116.4, 4.4, 9.2, 20.2, 20.2, 65.0 and 41.1, respectively (Cui et al. 2014).

Benzofuran lignans

Benzofuran lignans are determined by the presence of a furan juncture created from the linkage of C-7 to C-4′ through an oxygen atom and the direct linkage of C-8–C-3′. Due to the phenylpropanoid precursor units being connected at carbons other than C-8 to C-8′, these compounds are sometimes classified as 8,3′–neolignans. In addition to the isomeric possibilities caused by the stereogenic center in the 7, 8–dihydrofuran ring, there are also many possible modifications of the propyl chain of this class of molecules.

There were 26 benzofuran-type lignans isolated from plants and tested for antiviral activity (392–417) in the time period covered by this review (see Table 1 for source plants, antiviral activities, and references). The benzofuran lignans tested between 1998 and 2020 displayed the least antiviral activity of all of the classes of lignans. The most active benzofuran lignans were 403 and 406, however, there were none with EC₅₀ values ≤ 5 μM. There were no antiviral studies on synthetic lignans of this class.

Vladinol F (403), a lignan isolated from the leaves and stems of Schisandra micrantha (Yunnan, China), displayed anti-HIV-1 activity with an EC₅₀ value of 9.75 μM and a TI value of 27.45 (Li et al. 2005a). Balaphonin (406) was obtained from the leaves and stems of S. lancifolia (Yunnan, China). It showed anti-HIV-1 effects with an EC₅₀ value of 8.43 μM and a TI value of 4.3, respectively (Xiao et al. 2010b).

Neolignans

Neolignans are phenylpropanoid dimers connected at positions other than C-8/C-8′. Here, we are focusing on neolignans biosynthesized by connection of the C-3/C-3′ carbons in the phenylpropanoid precursors, or via an ether linkage.

Compounds 418–436 represent the 19 neolignans isolated from plants and tested for antiviral activity between 1998 and 2020 (see Table 1 for source plants, antiviral activities, and references). There were three plant-derived neolignans that exhibited EC₅₀ values ≤ 5 μM (424, 429, 436). Among this type of compounds, 424 may be considered as a lead molecule against HBV infection with a high TI value. There were 5 synthetic neolignans (437–441) made and assayed for antiviral activity.

Seven neolignans, (7′S,8′S)–trans–streblusol A (418), (7′R,8′S)–erythro–streblusol B (419), (7′S,8′S)–threo–streblusol B (420), 8′R-streblusol C (421), (8R,8′R)-streblusol D (422), threo-strebluslignanol (423) and magnolol (424) were isolated from the stem bark of Streblus asper (Moraceae, Guangxi, China). Magnolol (424) showed anti-HBV activities against HBsAg antigen with an EC₅₀ value of 2.03 μM and a TI value of 31.37, and HBeAg antigen with an EC₅₀ value of 3.76 μM and a TI value of 316.94 (Li et al. 2012a). (7R,8S,7′R,8′S)–erythro–Strebluslignanol H (428), -and honokiol (429) were isolated from the roots of the same plant. Among them, 429 exhibited anti-HBV activities with EC₅₀ values of 3.14 μM (TI = 21.5) on HBsAg and 4.74 μM (TI = 14.2) against HBeAg (Chen et al. 2012). Compound 429 also displayed an antiviral effect against HCVcc infection at non-toxic concentrations. It inhibited the cell entry of lentiviral particles pseudo-typed with glycoproteins from HCV genotypes 1a, 1b, and 2a, but not the VSV. The expression levels of the components of replication complex, NS3, NS5A and NS5B, were down-regulated by 429 in a dose-dependent manner in the concentration range of 10–30 μM. The compound inhibited HCV replication dose dependently in both genotypes 1b and 2a sub-genomic replicons in the concentration of 10 and 20 μM. Therefore, it was determined that 429 inhibited HCV infection by targeting cell entry and replication with an EC₅₀ value of 1.2 μM, an EC₉₀ value of 6.5 μM, and a TI (LD₅₀/EC₉₀) value of 5.4 (Lan et al. 2012). Furthermore, during the evaluation for activity against anti-SARS-CoV using a cell-based assay measuring SARS-CoV-induced cytopathogenic effects on Vero E6 cells, 424 and 429 showed inhibitory activity at the concentrations between 10 and 20 μM by cell-based CPE assay, and they displayed appreciable levels of anti-SARS virus bioactivity with EC₅₀ values ranging from 3.8 to 7.5 μM and the CC₅₀ values of > 65 μM (Wen et al. 2007).

In a separate study, 12 neolignans including 423, 424, magnolignan A (430), magnolignan A-2-O-β-D-glucopyranoside (431), isostrebluslignanaldehyde (432), isomagnolol (433), obovatol (434), strebluslignanol F (435) and (7′R,8′S,7″R,8″S)-erythro-strebluslignanol G (436) were isolated from the roots of S. asper (Guangxi, China) and evaluated for their anti-HBV activities using the HBV transfected HepG2.2.15 cells. The neolignan 424 and the dimeric neolignan 436 displayed activities against anti-HBV with EC₅₀ values of 2.03 (TI = 31.37) and 1.58 μM (TI = 74.90) for HBsAg, and with EC₅₀ values of 3.76 (TI = 16.94) and 3.24 μM (TI = 36.52) for HBeAg. They also showed HBV DNA replication with EC₅₀ values of 8.67 (TI = 7.34) and 9.02 μM (TI = 13.12), respectively (Li et al. 2013).

Five 1,4–benzodioxane neolignans eusiderin A (437), eusiderin B (438), eusiderin G (39), eusiderin M (440) and nitidanin (441) were synthesized and screened for their anti-HCV activity. They displayed inhibitory effects with the EC₅₀ values of 30, 20, 25, 50 and 200 μM and the TI values of 1.21, > 6.25, 1.91, 2.57 and 2.32, respectively (Pilkington et al. 2018).

Dibenzocyclooctadiene lignans and homolignans

Dibenzocyclooctadiene lignans are defined by having a C-2/C-2′ linkage as well as the usual C-8/C-8′ juncture of the phenylpropanoid precursor units. This endows them with a cyclooctadiene ring. Unlike dibenzocyclooctadiene lignans, which have both aromatic rings intact, homolignans lack one of the 6-carbon aromatic ring moieties. In some cases, homolignans possess a cyclohexadienone moiety, and in some instances, the cyclohexadienone moiety has been cleaved.

Between 1998 and 2020, 157 dibenzyocyclooctadiene lignans and homolignans (442–598) were isolated from plants and tested for antiviral activity, by far the most of any class of lignan over this time period (see Table 1 for source plants, antiviral activities, and references). This class of lignan had 20 compounds with antiviral activity (≤ 5 μM), but the most interesting, due to their potent activities (EC₅₀ ≤ 1 μM), are 480 and 591. There were no studies on synthetic dibenzyocyclooctadiene lignans or homolignans.

The lignans interiotherin B (443), angeloylgomisin R (444), schisantherin B (476), ( +)-gomisin K₃ (477), rubrisandrins A and B (478–479), ( ±)-gomisin M₁ (480), ( +)-gomisin M₂ (481), deoxyschisandrin (482), schisandrin (483), tigloylgomisin P (484), gomisin O (485), angeloylgomisin P (486), epigomisin O (487), methylgomisin R (488), ( +)-14-tigloylgomisin K₃ (489), 12-demethylwuweilignan I (490), schisandrene A (491), gomisin R (492), (R)-( +)-gomisin M₁ (493), ( +)-angeloylgomisin K₃ (494), dimethylgomisin J (495), rubrilignans A-B (496–497), schisantherin D (498), and gomisin J (499) were obtained from the extract of Schisandra rubriflora and their anti-HIV effects were evaluated (Chen et al. 2006; Li et al. 2008; Mu et al. 2011). Among them, rubrisandrin A (478), gomisin J (499), ( ±)-gomisin M₁ (480), ( +)-gomisin M₂ (481) and ( +)-gomisin K₃ (477) were active in the HIV growth inhibition assay with EC₅₀ values 11.3, 3.9, < 0.65, 2.4 and 5.7 μM, and TI values of > 5.7, 6.0, > 68, 19.4 and 7.4, respectively (Chen et al. 2006). Compound 480 possessed anti-HIV activity against a wide variety of HIV-1 and HIV-2 viral strains such as NL 4–3 (X4), Bal (R5), (B) BK132 (X4), (AE) 92TH001 (R5) and CBL-23 with EC₅₀ values in the range of 1–3 µM. Further investigation indicated that 480 was a non-nucleoside reverse transcriptase inhibitor (NNRTI). The studies in TZM-bl indicator cells showed 480 exerted inhibitory activity against both NL 4–3 and BaL, suggesting that it targets an early step in the HIV life cycle. Quantitative real-time PCR demonstrated that 480 blocked both early and late HIV-1 reverse transcription products (Han et al. 2015). Compounds 496 and 497 showed anti-HIV-1 activities with EC₅₀ values of 4.77 and 3.84 µM, and TI of 35.5 and 18.6, respectively (Mu et al. 2011).

Phytochemical investigation of Kadsura angustifolia (Schisandraceae, Yunnan, China) led to 19 dibenzocyclooctadiene lignans kadangustins A-G (510–516), schisantherins Q (517) and L (507), gomisin R (492), deangeloylschisantherin F (518), schisantherin F (519), binankadsurin A (520), kadsulignan K (521), epoxideschisandrin C (522), kadsurarin (373), kadsulignan N (466), schisantherin P (508) and kadsulignan L (509). Compound 520 showed anti-HIV activity with an EC₅₀ value of 3.86 µM (Gao et al. 2008).

From the stems of Kadsura heteroclita (Schisandraceae, Yunnan, China), dibenzocyclooctadiene lignans were obtained, including kadsulignan K (521), heteroclitins I (523) and J (524), acetoxyl oxokadsurane (525), benzoyl oxokadsurane (526), interiorin B (527), interiorin (451), heteroclitin D (453) and kadsurin (454). Compounds 451 and 527 exhibited anti-HIV-1 activity with EC₅₀ values of 3.3 and 2.9 µM, and therapeutic index values of 52.9 and 65.9, respectively (Pu et al. 2008b).

Twelve new dibenzocyclooctadiene lignans, marlignans A-L (558–573), were obtained from the leaves and stems of Schisandra wilsoniana (Yunnan, China). Compounds 562–564, 567–569 showed anti-HIV-1 activities with EC₅₀ values of 3.6, 3.3, 4.1, 4.1, 4.7, and 3.5 μM and the TI values of 8.7, 15.6, 6.7, 9.3, 7.7, and 16.4, respectively (Yang et al. 2010c). Two new dibenzocyclooctadiene ligans, schinegllignans A and B (613, 614), were isolated from the fruits of Schisandra neglecta (Schisandraceae, Yunnan, China). Compounds 613 showed anti-HIV-1 activities in C8166 cells with a EC₅₀ value of 4.6 and TI value of 18.5 (Duan et al. 2011).

From the stems of Schisandra neglecta (Schisandraceae, Sichuan, China), the new lignans neglignans A-B (590, 591) and E–G (592–594) and the known compounds rubschisantherin (583), gomisins D (585), T (595), F (596), angeloylgomisin Q (597) and schisphenin F (598) were obtained. Copmounds 583, 585, and 590–598 showed anti-HIV-1 activities with EC₅₀ values of 4.7, 9.8, 2.2, 1.4, 5.9, 3.5, 8.2, 8.2, 8.3, 11.5 and 8.3 μM, and TI values of 18.2, 18.9, 40.3, 55.3, > 33.7, > 58.0, 18.1, 15.1, 7.5, 7.4 and 17.8, respectively (Gao et al. 2013).

Norlignans and other lignoids

Norlignans are structures formed by the conjunction of two phenylpropanoid units followed by loss of one carbon from the skeleton. This section covers these compounds, as well as those formed from two phenylpropanoid units, but have undergone skeletal rearrangements or cleavages, termed lignoids. This includes secolignans as well as structures that have seemingly had one of the propyl side-chains completely removed.

During the time covered by this review, 32 norlignans and lignoids isolated from plants were tested for antiviral activity (599–630) (see Table 1 for source plants, antiviral activities, and references). Of the plant-derived norlignans and lignoids, only compounds 605 and 612 displayed antiviral activity at concentrations at or below 1 μM. We found no evidence of synthetic norlignans or lignoids bioassayed for antiviral activity.

Three 7,8-secolignans, marphenols A and B (605–606) together with 7,8-secoholostylone B (607), were isolated from the stems of Schisandra wilsoniana (Schisandraceae, Yunnan, China). Compounds 605–607 inhibited HIV-1_IIIB-induced syncytia formation with EC₅₀ values of 1.5, 4.5, 5.4 μM and TI values of 18.27, 4.33 and 9.19, respectively. In a further study of the anti-HIV-1 activity, 605 reduced p24 production in acute HIV-1_IIIB-infected C8166 cells with an EC₅₀ value of 9.0 μM, and inhibited primary isolate HIV-1TC-2 replication in PBMCs with an EC₅₀ value of 1.4 μM. However, the compound did not inhibit p24 expression and had no effects on cell to cell fusion in chronically infected H9 cells (Zhang et al. 2010).

(1S)–4–Hydroxy–3–[2–(4–hydroxyl–3–methoxy–phenyl)–1–hydroxymethyl–2–oxo–ethyl]–5–methoxy–benzaldehyde (612) was isolated from the seeds of Herpetospermum caudigerum (Cucurbitaceae, Sichuan, China) and displayed inhibitory activity against HBV on HBsAg and HBeAg secretions with EC₅₀ values of 0.34 and 4.83 × 10^–4 μM, respectively, and low cytotoxicity against HepG 2.2.15 cell line with a CC₅₀ value of 2.96 × 10⁵ μM (Yu et al. 2014).

Disscussion

Hundreds of lignans with anti-viral activities were reported from 66 different plant species, belonging to 43 genera, and 34 different families (Table 1). Among them, the genera Kadsura, Phyllanthus and Schisandra contained numerous active lignans with anti-HIV and anti-HBV activities.

Of the 630 lignans and lignoids covered in this review, 153 of them were arylnaphthalene lignans, 73 were aryltetralin lignans, 22 were dibenzylbutyrolactone lignans, 39 were dibenzylbutane lignans, 104 were tetrahydrofuranoid and tetrahydrofurofuranoid lignans, 26 were benzofuran lignans, 24 were neolignans, 157 were dibenzocyclooctadiene lignans and homolignans, and 32 were norlignans and other lignoids. Although aryltetralin and arylnaphthalene lignans have received the most attention in regards to synthesis, and structure–activity-relationship, due in large part to the clinical and commercial success of podophyllotoxin and the promising results of diphyllin (11) and helioxanthin (32), the other classes of lignans and lignoids are also deserving of increased scientific exploration as antiviral lead compounds (Table 2).

Table 2.

Comparison of antiviral lignan and lignoid classes from 1998–2020

Class	#a	# Natural	#(%) active at 1 μM or lessb	#(%) active at 5 μM or lessb	# Syntheticc
Arylnaphthalene	153	17	5 (29%)	6 (35%)	136
Aryltetralin	73	31	0 (0%)	3 (10%)	42
Dibenzylbutyrolactone	22	22	4 (18%)	7 (32%)	0
Dibenzylbutane	39	29	0 (0%)	2 (7%)	10
Tetrahydrofuranoid and tetrahydrofurofuranoid	104	104	5 (5%)	9 (9%)	0
Benzofuran	26	26	0 (0%)	0 (0%)	0
Neolignans	24	19	0 (0%)	3 (16%)	5
Dibenzocyclooctadiene lignans and homolignans	157	157	1 (1%)	20 (13%)	0
Norlignans and other lignoids	32	32	2 (6%)	8 (25%)	0

^aNumber of compounds in each class of lignan that have been tested for antiviral activity since 1998, and therefore have been included in this review

^bThe data was rounded to one significant figure to account for differences in accuracy of reported values. Only natural compounds tested for antiviral activities between 1998 and 2020 are included

^cNumber of synthetic compounds using the core structure of each class of lignan that have been tested for antiviral activity since 1998, and therefore have been included in this review

There remain multitudes of lignans and lignoids in all of the categories that have not been tested for antiviral activity, an endeavor that could reveal additional potent potential drugs. Further standardization of antiviral assays could also be beneficial in doing direct comparisons and for SAR studies (a poignant example is compound 627, which has two EC₅₀ values against HIV reported, one 44.68 μM, and one 104 μM).

Between 1963 and 2020, about 200 antiviral drugs were approved for treatment of viral infection. Most of them came from chemical synthesis or structural modifications of natural products (Clercq and Li 2016; Chaudhuri et al. 2018; FDA 2018, 2019, 2020). Although the isolated natural products normally exhibited moderate to weak antiviral activities, some did show excellent antiviral activities. For example, patentiflorin A (153), the 6-deoxyglucoside derivatives of diphyllin, which were isolated from Justicia plants, and shown to potently inhibit a broad spectrum of HIV-1 strains including some resistant strains with EC₅₀ values in the range of 15–37 nM (AZT: 77–95 nM) and mosquito-borne flavivirus such as ZIKV, DENV1, TBEV, WNV, JEV and EBV with EC₅₀ values ranged between 0.12–1.0 μM (Zhang et al. 2017a, 2017b; Martinez-Lopez et al. 2019). Helioxanthin (32) is an arylnaphthalene type lignan obtained from the roots of Heliopsis scabra Dunal (Asteraceae, Taiwan, China) and the aerial parts of Taiwania cryptomerioides Hayata (Taxodiaceae, Taiwan, China). It caught the attention of chemists because of its potent inhibition against HBV gene expression in vitro with an EC₅₀ value of 1 μM and an ID₅₀ value of 31 μM against CEM cell line (Yeo et al. 2005). In a study focusing on the molecular mode of action of 32 on HBV gene expression, this compound was found to suppress the surface antigen promoter (SP) II and the core promoter (CP) selectively, but it had no effect on SPI or the promoter for the X gene. In addition, the suppressive effects on both SPII and CP activity were liver-specific. In another study, compound 32 reduced the DNA-binding activity of the nuclear extract of HepA2 cells to the specific cis element of the HBV promoter for the core antigen, including peroxisome proliferator-activated receptors (PPARs), the PPAR binding site, and the transcription factors α-fetoprotein and specificity protein 1 (Sp1). Moreover, the ectopic expression of PPARγ or HNF4α partially reversed the suppression of HBV RNA by 32. Hence, compound 32 may represent a novel class of anti-HBV agents that can selectively modulate the transcriptional machinery of human liver cells to reduce HBV gene expression and replication (Tseng et al. 2008; Li et al. 2005b). More than 100 derivatives of helioxanthin were synthesised. Among them, the lactam 49 and the cyclic hydrazide derivative 59 exhibited significant inhibitory activity against wild mutant HBV with the EC₅₀ values of 0.08 and 0.03 μM, respectively (Yeo et al. 2005). Compound 49 also inhibited HBV against the drug resistant mutants W10 and DM2 with the EC₅₀ values of 0.004 and 0.0003 μM, respectively (Li et al. 2005b; Cheng et al. 2005a; Tseng et al. 2008). These studies revealed that natural lignans are an important source for the discovery of novel antiviral agents and should be further exploited as lead compounds. Since many lignans have demonstrated antiviral activities, extensive exploration of them through phytochemical studies, chemical synthesis, structure modification, structure–activity relationship analysis and mechanism of action studies could bring next generation of antiviral drugs.

Authors’ contributions

X. X. and D. W. carried out the collection and analysis of data, design of charts and drafted the manuscript. Y. L. participated in revision of manuscript. S. D. and H. Z. came up with the idea of review, edited, and implemented the revision of the manuscripts.

Funding

This work was supported by the Research Grants Council of the Hong Kong Special Administrative Region, China (Nos. HKBU12103618 and HKBU12103917), the Innovation and Technology Commission of Hong Kong Special Administrative Region, China (MHP/105/19), the Research Grants Council of the Hong Kong Baptist University (HKBU), Interdisciplinary Research Matching Scheme (No. RC-IRMS/15-16/02), the Hong Kong Scholars Program Foundation (No. XJ2015047), and Mr. Kwok Yat Wai and Madam Kwok Chung Bo Fun Graduate School Development Fund (WANG Dong-Ying).

Declarations

Conflict of interest

The authors declared that they have no conflicts of interest.